<DOC>
	<DOC>NCT02415829</DOC>
	<brief_summary>The study aims to identify the efficacy and safety of capecitabine plus oxaliplatin (XELOX) in patients with local advanced colorectal cancer.</brief_summary>
	<brief_title>Efficacy and Safety of Oxaliplatin Combined With Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1. Performance status (ECOG) 0~2 2. Histologically confirmed colon cancer. 3. No prior treatment 4. CTdefined T4 or lymph nodepositive colon cancer 5. Neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, and hemoglobin ≥ 8 g/dL Bilirubin level ≤ 1.0 x ULN 6. AST and ALT &lt; 1.5 x ULN 7. Serum creatinine ≤ 1.0 x ULN 8. Life expectancy of ≥ 3 months 9. Signed written informed consent 1. Final stage with cancer cachexia 2. Allergy for capecitabine or oxaliplatin 3. Any evidence of extrahepatic metastases and/or primary tumor recurrence 4. Severe organ failures or diseases, including: clinically relevant coronary disease, cardiovascular disorder or myocardial infarction within 12 months before study entry, severe psychiatric illness, severe infection and DIC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Neoajuvant chemotherapy</keyword>
</DOC>